Cormeto 250 mg capsule molli
GR-MET-19
Approved small_molecule active
Quick answer
Cormeto 250 mg capsule molli for patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome is a Approved program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Istituto Gentili S.r.l.
- Indication
- patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome
- Phase
- Approved
- Modality
- small_molecule
- Status
- active